Risk Assessment of Glycemic Instability During Illness Recovery

Abstract

Glycemic instability remains a significant clinical concern during the recovery phase of acute and chronic illnesses. Fluctuations in blood glucose levels can complicate patient outcomes, prolong hospitalization, and increase the risk of both immediate and long-term complications. This review examines the burden, underlying mechanisms, risk factors, clinical presentation, diagnostic approaches, management strategies, novel therapies, and current guideline recommendations for assessing and mitigating glycemic instability during illness recovery. The article synthesizes recent evidence and expert consensus to provide actionable insights for healthcare professionals managing this complex phenomenon.

Introduction

The period following acute illness represents a vulnerable window for patients with or at risk for dysglycemia. Factors such as ongoing inflammation, nutritional changes, medication adjustments, and variable organ function can contribute to unpredictable glucose fluctuations. Glycemic instability during recovery is associated with increased morbidity, delayed tissue healing, heightened infection risk, and exacerbation of comorbidities. Understanding the epidemiology, pathophysiology, and clinical implications of this phenomenon is essential for effective risk stratification and individualized patient care.

Epidemiology / Disease Burden

The prevalence of glycemic instability during illness recovery is substantial, particularly among populations with pre-existing diabetes, critical illnesses, and those exposed to stress hyperglycemia in the hospital setting. Studies estimate that up to 30% of individuals recovering from acute medical or surgical events experience significant glycemic variability, with a notable proportion developing hypoglycemic or hyperglycemic episodes. These fluctuations have been correlated with increased lengths of stay, readmission rates, and higher healthcare resource utilization. Notably, even non-diabetic individuals may experience transient dysglycemia during illness recovery, underscoring the broad relevance of this clinical entity.

Pathophysiology

Glycemic instability in the recovery phase results from a complex interplay of factors. Persistent counter-regulatory hormone elevation, insulin resistance induced by inflammatory mediators, and alterations in hepatic glucose production are prominent contributors. Diminished physical activity, reduced caloric intake, and fluctuating stress hormone levels further exacerbate glycemic variability. Additionally, the resolution of acute illness often necessitates withdrawal or adjustment of medications such as corticosteroids or parenteral nutrition, which can precipitate abrupt changes in glucose homeostasis. The interplay between endogenous insulin secretion, peripheral glucose uptake, and hepatic gluconeogenesis determines the magnitude and direction of glycemic excursions during recovery.

Risk Factors

Several patient- and illness-related factors increase the risk of glycemic instability during recovery. These include pre-existing diabetes (both type 1 and type 2), older age, chronic kidney or liver disease, malnutrition, polypharmacy (notably corticosteroids and beta-blockers), and recent major surgery or trauma. Iatrogenic factors, such as inappropriate insulin regimen adjustments or unrecognized enteral feeding interruptions, can further heighten risk. Additionally, patients recovering from severe infections, sepsis, or critical care admissions are particularly prone to persistent insulin resistance and glycemic variability.

Clinical Features

The clinical manifestations of glycemic instability during recovery are diverse. Patients may present with symptomatic hypoglycemia—manifested as diaphoresis, confusion, palpitations, or seizures—or with features of hyperglycemia, such as polyuria, polydipsia, blurred vision, and fatigue. Importantly, recurrent or unrecognized episodes may predispose to cardiac arrhythmias, impaired wound healing, increased susceptibility to infections, and cognitive dysfunction. In hospitalized settings, abnormal glucose readings may be detected incidentally, highlighting the need for vigilant monitoring even in asymptomatic individuals.

Diagnosis

Timely recognition of glycemic instability relies on systematic blood glucose monitoring, including both pre- and postprandial measurements. Point-of-care capillary glucose testing remains the mainstay in most clinical environments, while continuous glucose monitoring (CGM) offers enhanced detection of glycemic excursions, particularly in high-risk or critically ill patients. Laboratory evaluation should assess for potential precipitants, including renal or hepatic dysfunction, endocrine abnormalities, and medication effects. In select cases, evaluation of counter-regulatory hormone levels and C-peptide may elucidate underlying mechanisms.

Treatment & Management

Management hinges on individualized glycemic targets, taking into account the patient's baseline glycemic control, comorbidities, and recovery trajectory. For most patients, a moderate glycemic target (e.g., 140–180 mg/dL) balances the risks of hypoglycemia and hyperglycemia. Optimizing nutrition, minimizing abrupt medication changes, and careful titration of insulin or oral hypoglycemics are essential. Transition plans should anticipate changes in caloric intake, physical activity, and medication requirements as recovery progresses. In selected cases, CGM-guided insulin adjustments may improve stability and safety. Multidisciplinary collaboration—including endocrinologists, dietitians, and pharmacists—can further enhance outcomes.

Recent Advances / Emerging Therapies

Recent advances include the integration of real-time CGM in both inpatient and transitional care settings, which has been shown to reduce hypoglycemia rates and improve overall glycemic control. Novel insulin formulations with ultra-long-acting or glucose-responsive properties are under investigation for their potential to minimize variability during recovery. Additionally, emerging data support the role of incretin-based therapies and SGLT2 inhibitors in select populations, offering additional tools for tailored glycemic management. Ongoing research is focused on predictive analytics and machine learning algorithms to better identify patients at risk and to guide proactive interventions.

Guideline Recommendations

International guidelines stress the importance of regular glucose monitoring during and after acute illness, particularly in patients with diabetes or those who experienced stress hyperglycemia. The American Diabetes Association and other expert bodies recommend individualized glycemic targets, avoidance of hypoglycemia, and a gradual transition from intensive to maintenance regimens. Guideline-based protocols emphasize multidisciplinary education, medication reconciliation, and close outpatient follow-up to ensure sustained glycemic stability during recovery.

Conclusion

Glycemic instability during illness recovery represents a multifaceted clinical challenge with significant implications for patient outcomes. A thorough understanding of the epidemiology, mechanisms, risk factors, and management strategies is essential for effective risk assessment and intervention. Integration of novel monitoring technologies, individualized care plans, and adherence to evidence-based guidelines can reduce complications and promote optimal recovery. Ongoing research and interprofessional collaboration will further advance the care of patients vulnerable to glycemic instability in the post-illness setting.